Side-by-Side Comparison
MOTS-c vs NAD+: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how MOTS-c and NAD+ differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
MOTS-c
L2Also: Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that targets the AMPK pathway, studied for metabolic regulation and exercise mimicry.
NAD+
L3Also: Nicotinamide Adenine Dinucleotide, NAD
A coenzyme critical for cellular energy and DNA repair. Not technically a peptide, but commonly discussed alongside peptide therapies in the longevity space.
Side-by-side comparison
| Attribute | MOTS-c | NAD+ |
|---|---|---|
| Primary mechanism | Mitochondrial-Derived AMPK Activation | Sirtuin & PARP Cofactor |
| FDA status | Research Only | Research Only |
| Evidence level | Preclinical Evidence | Emerging Clinical Evidence |
| Human trials | None indexed | Yes (20+ indexed) |
| Studies indexed | 43 total (2 human, 22 animal) | 260 total (15 human, 85 animal) |
| Primary uses researched | Metabolic regulation, Exercise mimicry, Insulin sensitivity, Longevity | Cellular energy, DNA repair, Anti-aging, Neuroprotection, Addiction recovery (anecdotal) |
| Administration routes | subcutaneous | intravenous, oral, sublingual |
| Molecular weight | 2174.69 Da | 663.43 Da |
| Amino acids | 16 | — |
| Category | metabolic | longevity anti aging |
| WADA status | Prohibited | Permitted |
Key differences
Mechanism. MOTS-c acts primarily through mitochondrial-derived ampk activation, while NAD+ acts primarily through sirtuin & parp cofactor. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Both compounds share the same FDA status (Research Only), which means the practical pathway to access is similar for each.
Evidence base. NAD+ sits at a higher evidence level (L3) than MOTS-c (L2) under PeptideMark's L1–L5 methodology.
Research focus. Published research on MOTS-c has concentrated on metabolic regulation, exercise mimicry, insulin sensitivity. Research on NAD+ has concentrated on cellular energy, dna repair, anti-aging. These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | MOTS-c | NAD+ |
|---|---|---|
| Documented effects | 3 total | 6 total |
| Serious events | 0 | 0 |
| Common events | 1 | 2 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions (SC/IV) |
Strengths & limitations
MOTS-c
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Not FDA-approved for any indication — research use only
- Limited evidence base (L2)
- No indexed human clinical trials
- Prohibited in competitive sport under WADA
NAD+
Strengths
- Multiple human clinical trials (20+ indexed)
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
Representative studies
MOTS-c
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Reynolds JC, et al. · Nature Communications (2021)
MOTS-c treatment improved physical performance and muscle homeostasis in aged mice, mimicking some effects of exercise.
PubMed 33420028MOTS-c peptide administration enhances mitochondrial biogenesis in skeletal muscle
Lee C, Zeng D, Dibble C, et al. · Nature Metabolism (2022)
MOTS-c 10ng/kg daily for 8 weeks increased mitochondrial DNA copy number by 2.3-fold and citrate synthase activity by 1.8-fold in skeletal muscle.
PubMed 35715704NAD+
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias AJ, et al. · Nature Reviews Molecular Cell Biology (2021)
NAD+ levels decline with age across species, and restoring NAD+ has shown benefits in animal models for multiple aging-related conditions.
PubMed 33353981NMN supplementation improves metabolic and mitochondrial function in aged mice
Cantó C, Houtkooper RH, Pirinen E, et al. · Cell Metabolism (2012)
NMN restored muscle NAD+ to youthful levels; improved VO2max by 29% and exercise capacity by 56% in aged mice.
PubMed 22326221Frequently asked
What is the main difference between MOTS-c and NAD+?
MOTS-c is a mitochondria-derived peptide that targets the ampk pathway, studied for metabolic regulation and exercise mimicry. Its primary mechanism is mitochondrial-derived ampk activation. NAD+ is a coenzyme critical for cellular energy and dna repair. not technically a peptide, but commonly discussed alongside peptide therapies in the longevity space. Its primary mechanism is sirtuin & parp cofactor. The two differ in regulatory status (Research Only vs Research Only), strength of evidence (L2 vs L3), and the primary conditions for which each is researched.
Is MOTS-c or NAD+ FDA approved?
MOTS-c: Not FDA-approved. Research compound. A mitochondria-derived peptide discovered in 2015. NAD+: NAD+ itself is not FDA-approved as a drug. Precursors (NMN, NR) are sold as supplements. IV NAD+ is offered at clinics but not FDA-regulated.
How does the evidence base compare?
MOTS-c has 43 indexed studies (2 human, 22 animal) and is rated Preclinical Evidence. NAD+ has 260 indexed studies (15 human, 85 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can MOTS-c and NAD+ be compared directly?
MOTS-c and NAD+ come from different therapeutic categories (metabolic vs longevity anti aging), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are MOTS-c and NAD+ commonly stacked together?
There is no widely documented stacking protocol combining MOTS-c and NAD+ in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, MOTS-c or NAD+?
MOTS-c has 3 documented side effects (0 serious). NAD+ has 6 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are MOTS-c and NAD+ administered?
MOTS-c is typically administered via subcutaneous. NAD+ is typically administered via intravenous or oral or sublingual. Route differences affect onset, peak levels, and patient convenience.
Which is better, MOTS-c or NAD+?
"Better" depends on the therapeutic goal, regulatory context, and individual response. MOTS-c is most researched for metabolic regulation and exercise mimicry; NAD+ is most researched for cellular energy and dna repair. FDA status also matters: Research Only for MOTS-c vs Research Only for NAD+. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
MOTS-c →
Full profile
NAD+ →